Target Details
| UniProt AC | P23458 |
|---|---|
| Gene Symbol | JAK1 |
| Protein Name | Tyrosine-protein kinase JAK1 |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF18379 (FERM_F1) PF18377 (FERM_F2) PF17887 (Jak1_Phl) PF07714 (PK_Tyr_Ser-Thr) PF21990 (SH2_1) |
Summary
- Multi-target molecules 8,920
- Clinical molecules 14
- Avg pChEMBL 8.26
KEGG Pathways (28)
- Coronavirus disease - COVID-19
- EGFR tyrosine kinase inhibitor resistance
- Epstein-Barr virus infection
- Hepatitis B
- Hepatitis C
- Herpes simplex virus 1 infection
- Human T-cell leukemia virus 1 infection
- Human cytomegalovirus infection
- Human papillomavirus infection
- Influenza A
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Leishmaniasis
- Measles
- NOD-like receptor signaling pathway
- Necroptosis
- Osteoclast differentiation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Signaling pathways regulating pluripotency of stem cells
- Th1 and Th2 cell differentiation
- Th17 cell differentiation
- Toll-like receptor signaling pathway
- Toxoplasmosis
- Tuberculosis
- Viral carcinogenesis
Associated Diseases (1)
Active Molecules (8,920)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
NNBWJHDKGIUVBS
|
10.2 | Ki | 2 | — | |
NNBWJHDKGIUVBS
|
10.2 | Ki | 2 | — | |
NPGRFVWWRRRWNJ
|
10.2 | IC50 | 2 | — | |
NPXRGBHWBLKOFJ
|
10.2 | Ki | 2 | — | |
ODJLPNCPBKODCN
|
10.2 | Ki | 2 | — | |
ODJLPNCPBKODCN
|
10.2 | Ki | 4 | — | |
OIHUOYBHLAZFLD
|
10.2 | Ki | 4 | — | |
OPEXKUHHCQDSCD
|
10.2 | IC50 | 2 | — | |
PJTVQALTARBQFE
|
10.2 | Ki | 4 | — | |
PLYMRBURAGFOGH
|
10.2 | Ki | 2 | — | |
PLYMRBURAGFOGH
|
10.2 | Ki | 2 | — | |
POMTZDLWTMBAPX
|
10.2 | Ki | 2 | — | |
RNWGSYOIILQORV
|
10.2 | Ki | 4 | — | |
ROPIDDQBSGODHF
|
10.2 | Ki | 2 | — | |
ROPIDDQBSGODHF
|
10.2 | Ki | 2 | — | |
SFSZRYSHDLKEEE
|
10.2 | IC50 | 2 | — | |
UUVRCVXQRKLYNN
|
10.2 | Ki | 4 | — | |
UUVRCVXQRKLYNN
|
10.2 | Ki | 4 | — | |
UYRGIZHUWUTGEG
|
10.2 | Ki | 2 | — | |
VBLJPXQIIKILCU
|
10.2 | Ki | 2 | — | |
VBLJPXQIIKILCU
|
10.2 | Ki | 2 | — | |
WIICDYUXOKRMJM
|
10.2 | Ki | 2 | — | |
YJZCZHKRDVQYIX
|
10.2 | Ki | 2 | — | |
ZKKDNVPGFZDPRF
|
10.2 | Ki | 2 | — | |
ZKKDNVPGFZDPRF
|
10.2 | Ki | 2 | — | |
CUBORHOSMCXRBB
|
10.2 | IC50 | 2 | — | |
DWSHMTRKCGSRHM
|
10.2 | Ki | 4 | — | |
FTQBYQRDFCFCFN
|
10.2 | Ki | 4 | — | |
KQAJQVQIWBQIFM
|
10.2 | Ki | 4 | — | |
RYVTYSVONAMCBS
|
10.2 | Ki | 4 | — | |
SGCBQRMWMGNJGX
|
10.2 | IC50 | 4 | — | |
VQIIUJSNIKEMCK
|
10.2 | Ki | 4 | — | |
DVIAOMWIMTUTBT
|
10.2 | IC50 | 2 | — | |
VEDSSZUWHRJVAK
|
10.2 | IC50 | 2 | — | |
HYHLOTRVZFMLEU
|
10.2 | IC50 | 4 | — | |
CPQRGOCKOZRFQE
|
10.2 | IC50 | 4 | — | |
AKEWGBHTHRSCQD
|
10.2 | IC50 | 2 | — | |
CMGIHZWIMOWJLB
|
10.2 | IC50 | 2 | — | |
DXMFQKRSNZXZKZ
|
10.2 | IC50 | 2 | — | |
FNWGQOPCFGTWRX
|
10.2 | IC50 | 2 | — | |
GJEFXVFPINXVME
|
10.2 | IC50 | 2 | — | |
HHNQUSKCERMSSB
|
10.2 | Ki | 2 | — | |
ILEUVDWYQJSKJA
|
10.2 | IC50 | 4 | — | |
KTCIAOLTOISTRF
|
10.2 | Ki | 2 | — | |
MLFBAWATHWIRTN
|
10.2 | IC50 | 2 | — | |
OMIXJWWIWFMBQJ
|
10.2 | IC50 | 2 | — | |
PXTMUXZHALRTHU
|
10.2 | Ki | 2 | — | |
RSHOQZPUWNYQDO
|
10.2 | IC50 | 2 | — | |
RYVUECQMPLNULV
|
10.2 | IC50 | 2 | — | |
UWMZSPIJKZQCKF
|
10.2 | IC50 | 2 | — |